Scarica l'app Stockscreener
5.39
3.26%
0.17
Dopo l'orario di chiusura:
5.38
-0.010
-0.19%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXRX Giù?
Forum
Previsione
Recursion Pharmaceuticals Inc Borsa (RXRX) Ultime notizie
Recursion Pharmaceuticals Sees Elevated Call Volume and Implied Volatility - AInvest
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? - The Globe and Mail
With 68% institutional ownership, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a favorite amongst the big guns - simplywall.st
Morgan Stanley Assumes Coverage of Recursion Pharmaceuticals (RXRX) Stock with an Equal Weight Rating - MSN
Jensen Huang's Nvidia Owns 6 Stocks. Here's the Best of the Bunch. - The Motley Fool
(RXRX) Technical Data - news.stocktradersdaily.com
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing - sharewise.com
Recursion Pharma Surges: An Unexpected 12% Jump - StocksToTrade
Recursion Pharmaceuticals: Leveraging AI and Strategic Partnerships to Tackle Rare Diseases - AInvest
Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia - Insider Monkey
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program - Yahoo Finance
Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M - Yahoo Finance
11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds - Insider Monkey
RXRX: Market Moves and Future Projections - timothysykes.com
Recursion Pharmaceuticals: The AI Drug Discovery Play - Nasdaq
These 10 Stocks Are Making Big Moves - Insider Monkey
Biotech Stocks Climb With Recursion's Bold Move Forward - Finimize
Recursion Pharmaceuticals (RXRX) Drops on Profit-Taking - Insider Monkey
Here's Why Shares in Recursion Pharmaceuticals Surged Today - Yahoo Finance
Recursion Pharmaceuticals Rises With Rallybio Acquisition Move - Finimize
Recursion Pharmaceuticals Teams Up with MIT to Boost Drug Discovery - StocksToTrade
Recursion Pharmaceuticals Expands Strategic Reach with MIT Partnership - timothysykes.com
Why Is Microcap Rallybio Stock Trading Higher On Tuesday? - Benzinga
Recursion Pharmaceuticals Acquires Full Interest in Joint Hypophosphatasia Candidate From Rallybio - MarketScreener
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals - Business Wire
What's Happening With RXRX Stock? - Forbes
Recursion Pharmaceuticals Faces Financial Headwinds Amid Strategic Changes - timothysykes.com
Recursion Pharmaceuticals Stock Adjustments: What’s Next? - StocksToTrade
Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith? - The Globe and Mail
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today - Nasdaq
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process? - The Globe and Mail
MIT & Recursion Unveil Boltz-2, Accelerates Drug Discovery 1000x, Rivals Physics-Based Accuracy - Insider Monkey
Why This Wildcard Stock Could Be A Future Star - Barchart.com
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Morgan Stanley Trims Recursion (RXRX) Price Target, Maintains Equal Weight Rating - Insider Monkey
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors - Yahoo Finance
Transcript : Recursion Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 10 - MarketScreener
Recursion Pharmaceuticals (RXRX) Jumps 31% On Next-Gen AI - MSN
Recursion Pharmaceuticals stockholders elect three Class I directors - Investing.com Australia
Recursion Pharmaceuticals stockholders elect three Class I directors By Investing.com - Investing.com India
Recursion Pharmaceuticals Holds Annual Stockholder Meeting - TipRanks
Recursion Pharmaceuticals: Surging or Sinking? - timothysykes.com
Expert Outlook: Recursion Pharmaceuticals Through The Eyes Of 4 Analysts - Benzinga
Recursion Pharmaceuticals (RXRX): Morgan Stanley Adjusts Price Target | RXRX Stock News - GuruFocus
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
Recursion Pharma to reduce workforce by 20% - MSN
Why Recursion Pharmaceuticals Stock Is Plummeting Today - AOL.com
Recursion Pharmaceuticals price target lowered to $5 by Morgan Stanley - Investing.com Canada
Recursion Pharmaceuticals price target lowered to $5 from $8 at Morgan Stanley - TipRanks
Morgan Stanley Cuts Recursion Pharmaceuticals Price Target to $5 From $8, Maintains Equalweight Rating - MarketScreener
Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy? - MSN
Why Recursion Pharmaceuticals RXRX Could Be the NVDA of Biotech for NASDAQ:RXRX by TopgOptions - TradingView
Recursion to lay off 20% of workforce, narrows focus amid biotech downturn - MSN
Recursion Q1 2025 slides: AI platform advances pipeline amid earnings miss By Investing.com - Investing.com South Africa
Recursion Q1 2025 slides: AI platform advances pipeline amid earnings miss - Investing.com
3.40%
2.49%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):